Hubbry Logo
MucinMucinMain
Open search
Mucin
Community hub
Mucin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Mucin
Mucin
Mucin
View on Wikipedia
from Wikipedia

Micrograph showing cells with prominent mucin-containing intracytoplasmic vacuoles. Pap stain.
Identifiers
SymbolMucin
Membranome111

Mucins (/ˈmjuːsɪn/) are a family of high molecular weight, heavily glycosylated proteins (glycoconjugates) produced by epithelial tissues in most animals.[1] Mucins' key characteristic is their ability to form gels; therefore they are a key component in most gel-like secretions, serving functions from lubrication to cell signalling to forming chemical barriers.[1] They often take an inhibitory role.[1] Some mucins are associated with controlling mineralization, including nacre formation in mollusks,[2] calcification in echinoderms[3] and bone formation in vertebrates.[4] They bind to pathogens as part of the immune system. Overexpression of the mucin proteins, especially MUC1, is associated with many types of cancer.[5][6]

Although some mucins are membrane-bound due to the presence of a hydrophobic membrane-spanning domain that favors retention in the plasma membrane, most mucins are secreted as principal components of mucus by mucous membranes or are secreted to become a component of saliva.

Genes and proteins

[edit]

Human mucins include genes with the HUGO symbol MUC 1 through 22. Of these mucins, the following classes have been defined by localization:[7][8][9][10]

  • Secreted mucins in humans, with their chromosomal location, repeat size in amino acids (aa), whether they are gel-forming (Y) or not (N), and their tissue expression.[11]
Mucin gel chromosome repeat size (aa) tissue expression
MUC2 Y 11p15.5 23 Jejunum, ileum, colon, endometrium
MUC5A Y 11p15.5 8 Respiratory tract, stomach, conjunctiva, endocervix, endometrium
MUC5B Y 11p15.5 29 Respiratory tract, submandibular glands, endocervix
MUC6 Y 11p15.5 169 Stomach, ileum, gall bladder, endocervix, endometrium
MUC19 Y 12q12 19 corneal and conjunctival epithelia; lacrimal gland[12]
MUC7 N 4q13–q21 23 Sublingual and submandibular glands
MUC8 N 12q24.3 13/41 Respiratory tract, uterus, endocervix, endometrium
MUC9 N 1p13 15 Fallopian tubes
MUC20 N 3 19 kidney (high), moderately in placenta, lung, prostate, liver, digestive system

The major secreted airway mucins are MUC5AC and MUC5B, while MUC2 is secreted mostly in the intestine but also in the airway. MUC7 is the major salivary protein.[10]

Protein structure

[edit]

Mature mammalian mucins are composed of two distinct regions:[7]

Evolutionary classification

[edit]

The functional classification does not correspond to an exact evolutionary relationship, which is still incomplete and ongoing.[10] Known-related groups include:

  • The gel-forming mucins (2, 5AC, 5B, 6, 19) are related both to each other and to otogelin and von Willebrand Factor (PTHR11339).[14] Four of these occur in a well-conserved gene cluster (at 11p15.5 in humans).[15]
  • The EGF-like domain containing mucins. These include MUC3(A,B), MUC4, MUC12, MUC13, and MUC17.[16]
  • Some EGF-like mucins, plus MUC1 and MUC16, carry SEA domains, a vertebrate invention. It is unclear whether this points to a common origin among these transmembrane mucins.[14]
  • MUC21 and MUC22 are related to each other by sharing a C-terminal domain (PF14654). They also occur in a human gene cluster on 6p21.33.
  • MUC7 is a recent invention in placental mammals. It started as a copy in the secretory calcium-binding phosphoprotein (SCPP) gene cluster and rapidly gained PTS repeats.[17]

Function in humans

[edit]

Mucins have been found to have important functions in defense against bacterial and fungal infections. MUC5B, the predominant mucin in the mouth and female genital tract, has been shown to significantly reduce attachment and biofilm formation of Streptococcus mutans, a bacterium with the potential to form cavities.[18] Unusually, MUC5B does not kill the bacteria but rather maintains it in the planktonic (non-biofilm) phase, thus maintaining a diverse and healthy oral microbiome.[18] Similar effects of MUC5B and other mucins have been demonstrated with other pathogens, such as Candida albicans, Helicobacter pylori, and even HIV.[19][20] In the mouth, mucins can also recruit anti-microbial proteins such as statherins and histatine 1, which further reduces risk of infection.[20]

Eleven mucins are expressed by the eye surface epithelia, goblet cells and associated glands, even though most of them are expressed at very low levels. They maintain wetness, lubricate the blink, stabilize the tear film, and create a physical barrier to the outside world.[12]

Glycosylation and aggregation

[edit]

Mucin genes encode mucin monomers that are synthesized as rod-shaped apomucin cores that are post-translationally modified by exceptionally abundant glycosylation.

The dense "sugar coating" of mucins gives them considerable water-holding capacity and also makes them resistant to proteolysis, which may be important in maintaining mucosal barriers.

Mucins are secreted as massive aggregates of proteins with molecular masses of roughly 1 to 10 million Da. Within these aggregates, monomers are linked to one another mostly by non-covalent interactions, although intermolecular disulfide bonds may also play a role in this process.

Secretion

[edit]

Upon stimulation, MARCKS (myristylated alanine-rich C kinase substrate) protein coordinates the secretion of mucin from mucin-filled vesicles within the specialized epithelial cells.[21] Fusion of the vesicles to the plasma membrane causes release of the mucin, which as it exchanges Ca2+ for Na+ expands up to 600 fold. The result is a viscoelastic product of interwoven molecules which, combined with other secretions (e.g., from the airway epithelium and the submucosal glands in the respiratory system), is called mucus.[22][23]

Clinical significance

[edit]

Increased mucin production occurs in many adenocarcinomas, including cancers of the pancreas, lung, breast, ovary, colon and other tissues. Mucins are also overexpressed in lung diseases such as asthma, bronchitis, chronic obstructive pulmonary disease (COPD) or cystic fibrosis.[24] Two membrane mucins, MUC1 and MUC4 have been extensively studied in relation to their pathological implication in the disease process.[25][26][27] Mucins are under investigation as possible diagnostic markers for malignancies and other disease processes in which they are most commonly over- or mis-expressed.

Abnormal deposits of mucin are responsible for the non-pitting facial edema seen in untreated hypothyroidism. This edema is seen in the pretibial area as well.[28][page needed]

Non-vertebrate mucins

[edit]

Beyond the better-studied vertebrate mucins, other animals also express (not necessarily related) proteins with similar properties. These include:

Some other organisms produce mucilage that does not have a protein component, only polysacchides.

Cosmetic use

[edit]

Misuse of skincare products containing snail secretions of mucin have resulted in pain, swelling, and oozing.[31][32] Counterfeit versions of a Korean snail mucin product called COSRX have been selling online, putting users at risk.[33]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Mucin

View on Grokipedia
from Grokipedia
Mucins are a of high-molecular-weight glycoproteins that constitute the primary structural components of , a viscoelastic biological that coats and protects wet epithelial surfaces such as those in the respiratory, gastrointestinal, and reproductive tracts. Characterized by dense , where carbohydrates account for 50–90% of their mass, mucins feature a protein backbone rich in , , and serine residues, forming bottlebrush-like structures that enable gel formation, lubrication, and selective barrier properties against mechanical stress, pathogens, and toxins. Produced by specialized goblet and mucous cells, these glycoproteins exist in both secreted and membrane-bound forms, with over 200 unique glycan structures mediating interactions with microbes and the environment. Encoded by 21 genes in the MUC family (MUC1–MUC20 and MUC21), mucins are classified into secreted types, which polymerize via bonds to build the layer, and transmembrane types, which anchor to cell membranes. The seven secreted mucins include five gel-forming variants (MUC2, MUC5AC, MUC5B, MUC6, and MUC19) predominant in the intestines, airways, and , alongside non-gel-forming MUC7 and MUC8 found in and airways; membrane-bound mucins, numbering 11 (e.g., MUC1, MUC4, MUC16), feature cytoplasmic tails for signaling and extracellular domains for surface protection. Tissue-specific expression ensures tailored barrier functions, such as MUC2-dominated colonic mucus for microbial segregation or MUC5AC and MUC5B in airway clearance. Beyond physical protection, mucins contribute to immune modulation and microbial homeostasis by serving as nutrient sources and adhesion sites for commensal bacteria while trapping pathogens, with their glycans suppressing virulence and promoting a stable microbiota. Aberrant mucin glycosylation or expression underlies numerous pathologies, including chronic inflammatory conditions like cystic fibrosis and ulcerative colitis, as well as cancers where overexpressed mucins (e.g., MUC1) facilitate tumor invasion and immune evasion.

Overview and Classification

Definition and Properties

Mucins are high-molecular-weight glycoproteins that serve as the primary structural components of , forming protective barriers on epithelial surfaces throughout the body. They are produced by specialized goblet cells and other epithelial cells, and are encoded by a family of at least 21 MUC genes recognized by the Organization. Mucins can be classified into two main categories: secreted gel-forming mucins, such as MUC2 and MUC5AC, which contribute to the viscoelastic mucus gel, and cell-surface or transmembrane mucins, such as MUC1 and MUC4, which extend from the apical surface of epithelial cells to form the . Structurally, mucins feature a central protein backbone characterized by tandemly repeated sequences rich in , , and serine (PTS domains), which provide sites for dense . These O-glycans, initiated by the attachment of (GalNAc) to serine or residues, constitute 50-80% of the molecule's mass and form branched chains, resulting in a characteristic "bottlebrush" or extended rod-like conformation. The protein core also includes cysteine-rich domains at the N- and C-termini that facilitate through bond formation in secreted mucins, leading to large multimers with molecular weights often exceeding several million Daltons. The biochemical properties of mucins arise primarily from their extensive , which imparts high hydrophilicity, water-binding capacity, and resistance to , enabling the formation of hydrated gels. These gels exhibit viscoelastic behavior, balancing elasticity and to provide , hydration, and mechanical protection against shear forces and pathogens. Glycan diversity, including cores such as Core 1 (Galβ1-3GalNAc) and Core 2, often capped with or , further modulates charge, solubility, and interactions with microbes or signaling molecules.

Types and Nomenclature

Mucins are high-molecular-weight glycoproteins classified primarily into two major categories based on their structural features and cellular localization: secreted mucins and membrane-bound (transmembrane) mucins. This classification reflects their distinct roles in forming protective layers or anchoring to cell surfaces, respectively. Secreted mucins are further subdivided into gel-forming (oligomeric) types, which polymerize to create viscous barriers, and non-gel-forming (soluble or low-molecular-weight) types, which contribute monomeric or smaller oligomeric structures. Membrane-bound mucins, in contrast, possess a that tethers them to the plasma membrane, often extending heavily glycosylated ectodomains into the . The gel-forming secreted mucins include MUC2, MUC5AC, MUC5B, MUC6, and MUC19, which are characterized by cysteine-rich domains facilitating dimerization and subsequent multimerization via bonds and linker regions. Four of these (MUC2, MUC5AC, MUC5B, MUC6) cluster genetically on 11p15.5 (with MUC19 on 12q12), underscoring their evolutionary relatedness. For instance, MUC2 predominates in the intestinal tract, forming the primary component of the colonic layer, while MUC5AC and MUC5B are major constituents of airway and gastric , respectively. Non-gel-forming secreted mucins, such as MUC7 and MUC8, lack extensive polymerization domains and are typically monomeric or form small oligomers; MUC7, for example, is prominent in salivary secretions. Membrane-bound mucins encompass MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20, and MUC21, each featuring a single-pass transmembrane and variable cytoplasmic tails for signaling functions. These are distributed across multiple chromosomes, with notable clustering on 7q22 (MUC3A/B, MUC12, MUC17) and 3q29 (MUC4, MUC20). MUC1, the archetypal member, is ubiquitously expressed on epithelial surfaces and plays roles in and signaling, whereas MUC16 (also known as CA-125) is highly expressed in ovarian tissues. Some genes, like MUC14 (now EMCN, endomucin) and MUC9 (OVGP1, oviductal glycoprotein 1), exhibit atypical mucin features and are sometimes considered peripheral to the core family, while MUC22 remains poorly characterized.
CategoryExamplesKey Structural FeaturesChromosomal Locations
Gel-forming secretedMUC2, MUC5AC, MUC5B, MUC6, MUC19Cysteine-rich subdomains for ; von Willebrand factor-like domains11p15.5 (most)
Non-gel-forming secretedMUC7, MUC8Histatins or smaller repeat regions; no extensive oligomersVaried (e.g., 4q13.3 for MUC7)
Membrane-boundMUC1, MUC3A/B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20, MUC21; SEA module (in most); EGF-like motifs (in some)Multiple (e.g., 1q22 for MUC1, 19p13.2 for MUC16)
Nomenclature for human mucin genes follows the conventions of the HUGO Gene Nomenclature Committee (HGNC), which assigns symbols as "MUC" followed by a numeral (MUC1 through MUC21) in the approximate order of their discovery and molecular cloning, beginning in the late 1980s. This sequential numbering does not strictly correlate with functional or phylogenetic grouping but has been standardized to reflect their identification as mucin-encoding loci; for example, MUC1 was the first cloned transmembrane mucin in 1988, while MUC5AC and MUC5B were named for their gel-forming properties in airway mucins. Approved full names incorporate descriptive qualifiers, such as "cell surface associated" for membrane-bound types or "oligomeric mucus/gel-forming" for polymeric secreted ones, to denote structural distinctions. Pseudogenes or reclassified loci (e.g., MUC18 as MCAM, unrelated to mucins) are excluded from the official group, ensuring the list comprises 21 verified members as of current HGNC records (2025).

Molecular Biology

Encoding Genes

Mucins are encoded by a family of genes designated as MUC genes in humans, with 21 members identified by the HUGO Gene Nomenclature Committee. These genes were numbered sequentially based on the chronological order of their discovery, starting from MUC1 in the late 1980s. The MUC gene family exhibits significant structural diversity, but a common feature across most members is the presence of one or more large central exons containing variable number tandem repeats (VNTRs). These VNTRs encode proline-, serine-, and threonine-rich peptide domains that serve as scaffolds for extensive O-linked glycosylation, which constitutes the hallmark of mucin proteins. The length and sequence variability in these tandem repeat regions contribute to polymorphism and functional diversity among mucins. The MUC genes are broadly classified into two functional categories based on the structure of their encoded proteins: secreted mucins and membrane-bound (transmembrane) mucins. Secreted mucins, which form gel-like protective barriers on mucosal surfaces, include the gel-forming subtypes MUC2, MUC5AC, MUC5B, MUC6, and MUC19, as well as the non-gel-forming MUC7 and MUC8. Membrane-bound mucins, such as MUC1, MUC3A/B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20, and MUC21, feature a hydrophobic and a short cytoplasmic tail, enabling cell surface association and roles in signaling and adhesion. Additional genes like MUC9 (OVGP1), MUC14 (EMCN), and MUC22 have less defined classifications but share mucin-like domains. This dichotomy reflects evolutionary adaptations, with secreted forms emphasizing lubrication and trapping, while membrane forms facilitate cell-cell interactions. Chromosomally, the MUC genes are dispersed across multiple loci, with notable clustering observed for the major gel-forming secreted mucins. MUC2, MUC5AC, MUC5B, and MUC6 are tightly linked within a 400-kb on 11p15.5, oriented in the order MUC6-MUC2-MUC5AC-MUC5B. This suggests coordinated regulation and shared evolutionary origins from ancient tandem duplications. Other membrane-bound genes are scattered, such as MUC1 on 1q22, MUC4 and MUC20 on 3q29, and MUC16 on 19p13.2, reflecting independent evolutionary histories. The cluster on 11p15.5 is particularly significant, as polymorphisms in these genes, including VNTR length variations, influence mucin production and susceptibility to respiratory and gastrointestinal diseases.
GeneTypeChromosomal LocationKey Features
MUC1Membrane-bound1q22VNTR of 20-125 repeats encoding 60-bp units; involved in cell signaling.
MUC2Secreted (gel-forming)11p15.5Large central exon with two VNTR regions (48-bp and 69-bp repeats); predominant in intestinal mucus.
MUC3A/BMembrane-bound7q22.1Paired genes with large tandem repeats; expressed in gastrointestinal epithelia.
MUC4Membrane-bound3q29No VNTR but extensive EGF-like domains; largest mucin gene (~25 kb).
MUC5ACSecreted (gel-forming)11p15.5VNTR of 24-123 repeats (525-bp units); key in airway and gastric mucus.
MUC5BSecreted (gel-forming)11p15.5VNTR of 21-38 repeats (507-bp units); primary mucin in airway secretions.
MUC6Secreted (gel-forming)11p15.5VNTR of ~12 repeats (507-bp units); stomach-specific protective role.
MUC7Secreted (non-gel)4q13.3Short VNTR of 6-9 repeats (69-bp units); salivary mucin.
MUC16Membrane-bound19p13.2Extremely large (~14,000 aa) with ~156 SEA modules; ovarian cancer marker.
MUC20Membrane-bound3q29Smaller size; kidney and colon expression.
The structural organization of MUC genes typically includes signal peptide-coding exons at the 5' end, followed by the VNTR-containing central exon(s), cysteine-rich domains for dimerization or multimerization, and, for membrane-bound forms, 3' exons encoding transmembrane and cytoplasmic regions. This modular architecture allows for alternative splicing and copy number variations, particularly in the repeat regions, which can alter protein length and glycosylation capacity. For instance, the MUC5AC gene harbors multiple tandem repeat domains (P1-P6 variants), with recent genomic studies revealing human-specific expansions that enhance mucin diversity. Overall, the encoding genes underpin the biophysical properties of mucins, enabling their roles in mucosal protection and disease pathology.

Protein Architecture

Mucins are high-molecular-weight glycoproteins defined by their modular protein backbones, which feature densely O-glycosylated regions that confer extended, rigid structures essential for mucus formation and cellular protection. The core architecture consists of a signal peptide for secretion or membrane targeting, flanked by N- and C-terminal domains that mediate oligomerization and interactions, with a central proline-, serine-, and threonine-rich (PST) domain serving as the primary site of O-linked glycosylation. This glycosylation, often comprising 70-90% of the molecule's mass, creates a bottle-brush-like conformation that extends the protein up to 100-1000 nm in length, providing steric hindrance and lubrication. Secreted, gel-forming mucins such as MUC2, MUC5AC, MUC5B, MUC6, and MUC19 exhibit a conserved domain organization optimized for polymerization into viscoelastic networks. The includes multiple von Willebrand factor D (VWD) domains (e.g., VWD1-4) and cysteine-knot (CK) motifs that facilitate N-terminal trimerization and C-terminal dimerization through bonds, enabling the formation of linear multimers that cross-link via activity. The central mucin domain comprises variable number tandem repeats (VNTRs) of 10-30 rich in serines and threonines, where dense O-glycosylation with short, sialylated or sulfated glycans imparts rigidity and negative charge, crucial for expansion upon secretion. C-terminal cysteine-rich domains (CysD) further stabilize non-covalent interactions, while the overall architecture results in proteins exceeding 2 MDa, as seen in MUC2's ~5,000-residue backbone. Seminal studies on recombinant domain expression have elucidated these assembly mechanisms, confirming VWD domains' role in initial oligomerization. In contrast, membrane-bound mucins like MUC1, MUC4, MUC12, MUC13, and MUC16 integrate into the plasma membrane, forming a that modulates and adhesion. These proteins share an extracellular N-terminal region with a SEA (sea urchin sperm protein, enterokinase, agrin) domain, which undergoes autocatalytic cleavage to generate α and β subunits held by non-covalent bonds, and a VNTR-rich mucin domain analogous to secreted forms but shorter (e.g., 20-100 repeats in MUC1). The features a single transmembrane anchoring the protein, followed by a short cytoplasmic (10-70 residues) containing phosphorylation sites for intracellular signaling via kinases like PKC. MUC4 uniquely incorporates three EGF-like domains in its extracellular region, enabling interactions with receptor tyrosine kinases such as ErbB2 to promote anti-adhesive and proliferative signals. O-glycosylation in these mucins is sparser and more variable, often truncated in cancers, altering the extended structure to expose protein epitopes. Structural analyses, including those of recombinant SEA domains, highlight the cleavage site's conservation across species, underscoring its role in subunit maturation.

Evolutionary Perspectives

Mucins, particularly the gel-forming subtypes, originated early in metazoan evolution, with proteins exhibiting characteristic D (VWD), VWD C8 (VWE), and TIL domains identified in the cnidarian Nematostella vectensis. These structural modules suggest that ancestral gel-forming mucins evolved as protective adaptations in basal animals, predating the divergence of major metazoan lineages. Gel-forming mucins are also present in non-vertebrate chordates such as the sea squirt Ciona intestinalis and the lancelet Branchiostoma floridae, indicating broad conservation across invertebrates and early vertebrates. In vertebrates, the number of gel-forming mucin genes varies significantly, reflecting lineage-specific expansions. Humans possess five such genes (MUC2, MUC5AC, MUC5B, MUC6, and MUC19), while teleost fishes like zebrafish (Danio rerio) and pufferfish (Takifugu rubripes) have only one identifiable MUC2 ortholog each. A notable expansion occurs in amphibians, where the frog Xenopus tropicalis encodes at least 25 gel-forming mucins, including 16 MUC2 homologs and nine MUC5-type proteins, likely driven by gene duplication events that enhanced mucus production in moist environments. Membrane-bound mucins, in contrast, show distinct evolutionary trajectories; for instance, human MUC1 is mammal-specific and derived from a heparin sulfate proteoglycan ancestor via acquisition of a SEA domain, while MUC4 and MUC16 evolved from separate progenitors involving NIDO, AMOP, VWD, and multiple SEA domains, respectively, with no close sequence similarity beyond shared motifs. In mammals, mucin evolution frequently involves the of non-mucin, proline-rich precursor proteins that acquire proline-threonine-serine (PTS)-rich exonic repeats, enabling O-glycosylation and gel-forming —a termed "mucinization." This mechanism accounts for 15 independent, lineage-specific events, explaining the origin of all 28 mucins in the secretory calcium-binding phosphoprotein (SCPP) locus. A representative example is the rodent-specific MUC10, which arose from the proline-rich protein Prol1 through tandem repeat expansions (up to 42 copies in some ) and shifts in expression to salivary glands, adapting to dietary and pathogenic pressures. Such rapid diversification via repeat insertions allows mucins to evolve novel functions without whole-gene duplications, highlighting a key innovation in mammalian adaptation. Recent genomic studies have revealed that the MUC19 in some modern human populations carries haplotypes introgressed from Denisovans, suggesting adaptive advantages in .

Biochemistry

Glycosylation Mechanisms

Mucin-type O-glycosylation represents the predominant post-translational modification in mucins, characterized by the dense attachment of O-linked glycans to serine and threonine residues within the protein's proline-, threonine-, and serine-rich (PTS) domains. This process occurs primarily in the Golgi apparatus and is essential for the structural expansion, solubility, and protective functions of mucins, with up to 80-90% of amino acids in these domains being glycosylated. The initiation step involves the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the hydroxyl group of serine or threonine, forming the Tn antigen (GalNAcα1-O-Ser/Thr), catalyzed by a family of over 20 polypeptide N-acetylgalactosaminyltransferases (ppGalNAcTs or GALNTs). These enzymes exhibit isoform-specific substrate preferences and tissue distribution, with examples like GALNT1 implicated in ovarian cancer progression and GALNT12 in colorectal carcinoma. Following initiation in the cis-Golgi, the Tn antigen undergoes elongation to form one of several core structures, primarily cores 1 through 8, though cores 1-4 predominate in mucins. Core 1 (T antigen, Galβ1-3GalNAcα1-O-Ser/Thr) is synthesized by the (C1GALT1), which requires the molecular chaperone COSMC to maintain its activity and prevent degradation; mutations or silencing of COSMC lead to persistent Tn expression and are associated with aberrant mucin in diseases. Alternative cores include core 2 (GlcNAcβ1-6(Galβ1-3)GalNAcα1-O-Ser/Thr), formed from core 1 by core 2 β1,6-N-acetylglucosaminyltransferases (C2GnT1-3); core 3 (GlcNAcβ1-3GalNAcα1-O-Ser/Thr), generated directly from Tn by β1,3-N-acetylglucosaminyltransferase 6 (C3GnT6); and core 4, an extension of core 3 with an additional GlcNAc branch via C2/4GnT. These core formations occur in the medial Golgi and diversify the glycan repertoire, with core 1 being the most common in secretory mucins like MUC2 and MUC5AC. Subsequent extension and modification in the trans-Golgi and trans-Golgi network involve the addition of monosaccharides such as , , , and , mediated by a cascade of glycosyltransferases. For instance, poly-N-acetyllactosamine (poly-LacNAc) chains are built by alternating β1,4-galactosyltransferases (β4GalTs) and β1,3-N-acetylglucosaminyltransferases (β3GnTs), while sialylation—critical for mucin charge and viscosity—occurs via sialyltransferases like ST6GalNAc-I, which adds α2,6-linked to Tn to form sialyl-Tn (STn) . Fucosylation by fucosyltransferases introduces Lewis antigens (e.g., Lewis A or X), enhancing mucin interactions with and pathogens. In mucins, these extensions create heterogeneous, branched glycan trees that contribute to the gel-forming properties, with the degree of sialylation and sulfation influencing and . The following table summarizes the primary core structures in mucin O-glycosylation, highlighting key enzymes and their linkages:
CoreStructureInitiating EnzymeLinkage from Tn or PrecursorPrevalence in Mucins
1 (T)Galβ1-3GalNAcα1-O-Ser/ThrC1GALT1 (with COSMC)β1-3 Gal to TnHigh (e.g., MUC1, MUC5AC)
2GlcNAcβ1-6(Galβ1-3)GalNAcα1-O-Ser/ThrC2GnT1-3β1-6 GlcNAc to Core 1Moderate (branching in MUC2)
3GlcNAcβ1-3GalNAcα1-O-Ser/ThrC3GnT6β1-3 GlcNAc to TnVariable (gastric mucins)
4GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα1-O-Ser/ThrC2/4GnTβ1-6 GlcNAc to Core 3Low (respiratory mucins)
This stepwise, enzyme-driven assembly ensures the mucin's glycan density and diversity, which are tightly regulated to maintain physiological roles but frequently disrupted in pathological states.

Polymerization and Gel Formation

Gel-forming mucins, such as MUC2, MUC5AC, and MUC5B, undergo a two-step process that assembles individual monomers into high-molecular-weight polymers capable of forming viscoelastic gels. In the , C-terminal cysteine knot (CTCK) domains facilitate dimerization through three intermolecular bonds, creating stable dimeric units. This initial step ensures proper alignment for subsequent . Subsequent N-terminal assembly occurs in the trans-Golgi network, where low (around 6.0) triggers the formation of -linked polymers via D3 domains, which form interlocked, helical assemblies spaced approximately 13.7 nm apart. These D3 structures, connected by bonds (e.g., Cys1088-Cys1088 and Cys1130-Cys1130), enable head-to-head linkages between dimers, extending the polymer length to millions of daltons. The CysD domain plays a pivotal role in stabilizing these polymeric filaments, exhibiting a novel β-sandwich fold that binds calcium ions and positions opposite to D3 assemblies. Cryo-electron studies reveal that CysD organizes the polymers into beaded filaments, with O-glycosylated proline-threonine-serine (PTS) regions—spanning about 100 —linking the N- and C-terminal domains and preventing premature entanglement during . Diversity in CysD domains across mucin types contributes to species-specific properties; for instance, MUC2 features two CysD subdomains, while some non-mammalian homologs have variations that influence efficiency. bonds in CysD further reinforce the linear scaffold, essential for the structural integrity required for gelation upon . Gel formation arises from the entanglement and cross-linking of these polymers post-secretion, modulated by ionic and non-covalent interactions. Upon into neutral environments, the densely glycosylated mucin backbone (comprising over 80% carbohydrates) hydrates rapidly, expanding the polymers up to 1000-fold and forming a three-dimensional network. Calcium-mediated cross-links, facilitated by non-mucin proteins like trefoil factor family (TFF) peptides, enhance inter-polymer associations, while hydrogen bonding between N- and C-terminal domains and the glycosylated regions promotes . Rheological analyses show that gelation occurs above 15-20 mg/mL mucin concentration, yielding a storage modulus (G') exceeding the loss modulus (G''), with yield stresses around 3 Pa indicative of solid-like behavior. Disruption of disulfides (e.g., by DTT) or calcium (e.g., by EDTA) abolishes this network, underscoring the cooperative action of covalent and ionic bonds in barrier function.

Biosynthesis and Secretion

Mucins are high-molecular-weight glycoproteins synthesized primarily by specialized epithelial cells, such as goblet cells in the intestine and mucous cells in the respiratory and reproductive tracts. The biosynthesis begins with the translation of mucin precursor proteins (apomucins) on ribosomes in the , followed by translocation into the (ER) where initial folding and N-linked occur. In the ER, cysteine-rich domains form disulfide bonds that facilitate dimerization of apomucins, such as MUC2, creating rod-like structures essential for subsequent . This process is assisted by protein disulfide isomerases (PDIs) like PDIA1-6 and the endoplasmic reticulum protein AGR2, which prevent misfolding under the high synthetic load. Transport from the ER to the Golgi apparatus requires ATP-dependent chaperones like Tango1, after which extensive takes place in the Golgi. Initiation of O-glycosylation is catalyzed by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts), such as GALNT1-12, adding (GalNAc) to serine and residues in proline-rich domains. Subsequent elongation by glycosyltransferases, including B3GNT1-9, adds diverse chains comprising , , , and , resulting in mucins that are over 80% by weight. For gel-forming mucins like MUC5AC and MUC5B, N- and C-terminal cysteine knots enable multimerization into large polymers exceeding 10 MDa, packaged into secretory granules under low and high calcium conditions. These granules mature as they move toward the apical membrane, with the entire biosynthetic pathway being energy-intensive and tightly regulated to match physiological demands. Secretion of mucins occurs via regulated , where granules fuse with the plasma membrane in response to stimuli. Baseline secretion is maintained by spontaneous calcium oscillations through ryanodine receptors (RYR2) and receptors (IP3R), triggering low-level release at calcium concentrations below 1 µM via mechanisms involving KChIP3. Stimulated secretion, which can increase rates dramatically, is induced by neural, hormonal, or inflammatory signals, such as , , or NLRP6 activation, leading to calcium influx via channels like /2 and synaptotagmin-2 (Syt2) at higher concentrations (>10 µM). Fusion is mediated by SNARE proteins (e.g., STX1A, VAMP5) and Rab GTPases (e.g., RAB3, RAB27), positioning granules at the apical surface. Upon release, the low-calcium, neutral pH environment, aided by (HCO₃⁻) secretion, causes rapid hydration and unfolding, expanding the mucin network up to 1000-fold to form the viscoelastic gel. This process is conserved across tissues, with dysregulation linked to diseases like .

Physiological Roles

Protective and Lubricating Functions

Mucins, as the primary components of , form a viscoelastic that serves as a frontline protective barrier in epithelial tissues, shielding underlying cells from mechanical stress, chemical insults, and microbial . This gel-like structure arises from the high molecular weight and extensive of mucins, creating a hydrated network with pore sizes typically ranging from 50 nm to 1 μm, which selectively filters particles and pathogens while allowing nutrient diffusion. In the , for instance, the MUC2 mucin organizes a firmly adherent inner mucus layer that remains sterile, preventing bacterial penetration to the , as demonstrated in studies of colonic mucus organization. Similarly, in the , MUC5B contributes to a periciliary layer that protects cilia from and mechanical damage during airflow, facilitating . The protective role extends to antimicrobial defense through mucins' ability to trap and neutralize microbes via glycan-mediated binding and steric hindrance. For example, MUC1 mucin limits Helicobacter pylori adhesion in the stomach by presenting decoy receptors and physical barriers, reducing infection risk. In the oral cavity, salivary mucins such as MUC5B and MUC7 bind cariogenic bacteria like Streptococcus mutans, suppressing their virulence while providing glycans that support beneficial microbiota like Akkermansia muciniphila. Additionally, mucins protect against environmental stressors, such as low pH in gastric mucus (MUC5AC), where the gel maintains integrity at pH 1–2 to shield the epithelium from acid and pepsin. In the ocular surface, soluble mucins like MUC5AC and MUC7 clear allergens and debris, preventing inflammation. Lubrication is a critical function enabled by the mucins' viscoelastic properties, which reduce and shear forces during physiological movements. The extended, bottle-brush-like structure of mucin polymers, stabilized by bonds and hydrated by glycosylated domains, allows for reversible cross-linking that imparts both elasticity and flow under stress. In the eyes, a thin, watery mucin layer facilitates smooth blinking without damaging the , with spinnability and low coefficients essential for this process. Salivary mucins, particularly MUC5B, form entangled networks that lubricate the during and speech, enhancing bolus transport and preventing tissue abrasion. In the intestines, the MUC2-dominated provides slipperiness for peristaltic propulsion of food, protecting the from mechanical injury while aiding nutrient absorption. Cervical mucins exhibit pH-responsive , transitioning from gel-like during to more fluid states to support transport and .

Interactions with Microbiota

Mucins, particularly the gel-forming MUC2 in the intestine, form a dynamic mucus barrier that interacts closely with the gut microbiota, serving as both a protective niche and a nutrient source for commensal bacteria. The intestinal mucus consists of an inner layer firmly attached to epithelial cells and largely devoid of bacteria, and an outer, looser layer colonized by microbiota, which prevents direct microbial contact with the host epithelium while allowing symbiotic exchanges. This stratified structure is maintained through mucin glycosylation and secretion, modulated by microbial signals that influence goblet cell activity and mucin production. Commensal degrade mucin glycoproteins using specialized enzymes, primarily carbohydrate-active enzymes (CAZymes) such as hydrolases and sulfatases, to access the underlying O-linked glycans and protein core. This degradation releases monosaccharides and oligosaccharides, which ferment into (SCFAs) like , propionate, and butyrate, providing energy for the and the host. Key mucin degraders include , which targets terminal sialic acids and sulfated glycans; thetaiotaomicron, utilizing a broad range of glycan structures via polysaccharide utilization loci (PULs); and gnavus, which produces sialidases to initiate breakdown. Cross-feeding among species, where primary degraders supply metabolites to secondary fermenters like spp., enhances microbial community stability and diversity. These interactions foster , as SCFAs from strengthen the mucus barrier by promoting mucin and reducing , while microbial regulates host mucin and patterns. Disruptions in mucin-microbiota balance, such as reduced A. muciniphila abundance or altered degradation in , impair barrier integrity and contribute to diseases including (IBD), , and . For instance, in IBD models, defective MUC2 leads to thinner mucus layers and bacterial penetration, exacerbating . Dietary interventions enhancing mucin-compatible glycans can restore these interactions, underscoring their therapeutic potential.

Roles in Non-Vertebrates

Mucins and mucin-like proteins have been identified in a variety of non-vertebrate organisms, tracing their evolutionary origins to early metazoan lineages such as Porifera (sponges), (jellyfish and corals), and (comb jellies). These proteins, characterized by their glycosylated structures and gel-forming capabilities, contribute to mucus layers that provide foundational protective and adaptive functions across invertebrate phyla. In these basal metazoans, mucins facilitate epithelial coverage and barrier formation, predating the more specialized roles seen in vertebrates. In mollusks, such as gastropods (snails) and bivalves, mucins play critical roles in locomotion, environmental interaction, and defense. Snail foot mucus, rich in mucin glycoproteins with tandem repeat domains and extensive O-glycosylation, enables adhesion to diverse surfaces, allowing movement over rough or vertical terrains while minimizing energy expenditure. These mucins also provide lubrication to reduce friction during gliding and hydration to prevent desiccation in terrestrial or amphibious species like Cornu aspersum. In bivalves and gastropods, mucins form physical barriers in the mantle and gill epithelia, shielding against pathogens, pollutants, and mechanical damage from water currents or sediment. Bioinformatic analyses have identified up to 20 mucin genes in snail transcriptomes, highlighting their evolutionary divergence and adaptation for these multifunctional roles. Arthropods, particularly insects, utilize mucin-like proteins for gut protection and reproductive processes. In the lepidopteran midgut of species like Trichoplusia ni (cabbage looper) and Manduca sexta (tobacco hornworm), intestinal mucins form a glycoprotein-rich layer that acts as a physical and biochemical barrier, preventing pathogen adhesion and invasion by bacteria or viruses. For instance, the peritrophic matrix in insect guts incorporates mucins that resist digestive enzymes while trapping and expelling microbes; baculovirus enhancins target and degrade these mucins to enhance viral infectivity, underscoring their defensive function. In the hemipteran Nilaparvata lugens (brown planthopper), a mucin-like protein (NlESMuc) with over 1,000 O-glycosylation sites is essential for oviposition, contributing to eggshell integrity and proper egg deposition into plant tissues, thereby ensuring reproductive success. In chordates like ascidians (Ciona robusta), mucins integrate with to bolster gut immunity. -rich gels tether immune effectors, such as V region-containing chitin-binding proteins (VCBPs), which bind and opsonize , limiting colonization and shaping the . This mechanism reflects a convergent strategy for mucosal defense, analogous to systems but adapted to . In cnidarians, mucins similarly lubricate epithelia, maintain hydration, and protect against microbial threats in marine environments.

Clinical and Applied Aspects

Involvement in Diseases

Mucins play a pivotal role in various diseases, particularly those affecting mucosal surfaces, where their aberrant expression, , or secretion disrupts protective barriers and contributes to . In epithelial cancers, transmembrane and secreted mucins are frequently overexpressed, shielding tumor cells from immune surveillance and while promoting and . For instance, MUC1 is upregulated in over 90% of , pancreatic, and adenocarcinomas, activating signaling pathways such as and β-catenin to enhance cell and proliferation. Similarly, MUC4 interacts with receptor tyrosine kinases like ErbB2 in pancreatic and ovarian cancers, suppressing and facilitating tumor growth, with its expression correlating to poor prognosis in these malignancies. MUC16, recognized as the CA125 antigen, is elevated in approximately 80% of ovarian cancers, aiding in to mesothelin-expressing sites during peritoneal and serving as a for disease monitoring. In gastrointestinal disorders, mucin dysregulation compromises the intestinal mucus barrier, exacerbating and microbial invasion. In (IBD), including and , MUC2—the predominant gel-forming mucin in the colon—is significantly reduced, leading to a thinner, more penetrable mucus layer that allows bacterial translocation and chronic . Studies in MUC2-deficient mice demonstrate spontaneous development, underscoring its essential role in maintaining barrier integrity. Altered of mucins, such as decreased sulfation and increased sialylation, further weakens the barrier in , promoting depletion and disease severity. In contrast, transmembrane mucins like MUC1 and MUC4 are upregulated in IBD, potentially modulating inflammatory signaling but contributing to in chronic cases. Respiratory diseases highlight mucins' involvement in mucus hypersecretion and obstruction. In cystic fibrosis (CF), mutations in the CFTR gene impair chloride transport, resulting in dehydrated, viscous mucus enriched with MUC5AC and MUC5B, which clogs airways and fosters chronic infections by pathogens like Pseudomonas aeruginosa. This mucin hypersecretion, driven by epidermal growth factor receptor signaling, perpetuates inflammation and lung damage, with MUC5B variants influencing disease severity in some cohorts. In chronic obstructive pulmonary disease (COPD) and asthma, elevated MUC5AC production—stimulated by cytokines like IL-13—leads to mucus plugs that impair clearance and exacerbate airflow obstruction. MUC5AC levels in sputum correlate with reduced FEV1 in COPD patients, indicating its role in disease progression and acute exacerbations. Beyond these, mucins influence infectious diseases by either entrapping pathogens or being targeted for degradation. In gastritis, bacterial enzymes disrupt MUC1, facilitating epithelial adhesion and ulcer formation. In metabolic and chronic inflammatory conditions, such as , altered mucin promotes and , linking mucosal barriers to systemic pathology. Overall, these dysregulations underscore mucins as key mediators in disease, with therapeutic strategies targeting their expression showing promise in preclinical models.

Therapeutic and Diagnostic Potential

Mucins exhibit substantial therapeutic and diagnostic potential due to their aberrant expression, altered glycosylation, and functional roles in disease pathogenesis, particularly in cancers and chronic inflammatory conditions. In oncology, mucins serve as biomarkers for early detection and monitoring, with deregulated forms detectable in bodily fluids via non-invasive methods like liquid biopsies. For instance, MUC16, also known as CA125, is a well-established serological marker for ovarian cancer, overexpressed in approximately 80% of epithelial cases, enabling detection through enzyme-linked immunosorbent assays (ELISA) with sensitivities exceeding 80% in advanced stages when combined with other markers like HE4. Similarly, MUC1 contributes to CA15-3 assays for breast cancer monitoring, while panels involving MUC5AC and CA19-9 improve pancreatic cancer detection sensitivity to 67-75% and specificity to 48-83%, surpassing single-marker performance. Beyond cancer, mucin profiles, such as reduced MUC2 levels and altered O-glycosylation, act as indicators of disease severity in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, where immunohistochemistry and serological analysis reveal barrier dysfunction. In cystic fibrosis (CF), elevated intestinal MUC1 expression correlates with mucus obstruction, supporting mucin gene expression as a potential diagnostic adjunct to CFTR testing. Therapeutically, mucins are targeted to disrupt tumor progression and restore mucosal barriers. In cancer, MUC1 has emerged as a pan-cancer target due to its overexpression in up to 90% of epithelial malignancies, prompting immunotherapies like the L-BLP25 (tecemotide), which was tested in a phase III trial for non-small cell but did not meet its primary endpoint for overall survival benefit despite eliciting T-cell responses against aberrant MUC1 . Antibody-based approaches include clivatuzumab tetraxetan, a radiolabeled anti-MUC5AC that was evaluated in phase I/II trials for . Small-molecule inhibitors, such as GO-201, prevent MUC1-C oligomerization, inducing and tumor regression in and xenografts via pathways involving Bax and activation. For MUC16 in , antibody-drug conjugates block interactions, enhancing cytotoxicity in preclinical models. As of 2025, emerging therapies include MUC1-targeted antibody-drug conjugates (ADCs), CAR-T cell therapies against MUC17 in gastric cancer, and radiopharmaceuticals, showing promise in early clinical studies for various epithelial malignancies. In inflammatory diseases, strategies focus on modulating mucin production and secretion to reinforce mucosal defenses. In IBD, cytokines like IL-10 and IL-33 promote MUC2 synthesis and goblet cell differentiation, reducing endoplasmic reticulum stress and enhancing mucus thickness in dextran sulfate sodium-induced colitis models, as demonstrated in Muc2-deficient mice that spontaneously develop inflammation. Fecal microbiota transplantation (FMT) restores mucin-degrading bacteria balance, improving barrier integrity in infection-associated colitis. For CF, therapies targeting CFTR-mucin interactions, such as potentiators that normalize mucin hydration and secretion, address viscous mucus accumulation, with preclinical evidence showing reduced inflammation via autophagy modulation. Natural products inhibiting oncogenic signaling in mucin pathways also hold promise for both cancer and IBD by attenuating hypersecretion. These approaches underscore mucins' versatility as targets, with ongoing clinical trials emphasizing combination therapies for improved efficacy.

Cosmetic and Industrial Applications

Mucins, particularly those derived from secretions, have gained prominence in the for their hydrating and regenerative properties. mucin, rich in glycoproteins, , , and , is incorporated into skincare products such as serums, creams, and essences to enhance moisture retention, reduce fine lines, and promote synthesis. These components facilitate proliferation and extracellular matrix assembly, leading to improved elasticity and dermal density, as demonstrated in a four-week clinical study where 80% mucin creams reduced wrinkles in participants. Additionally, mucin's antimicrobial peptides and antioxidants, including and glutathione S-transferase, help mitigate inflammation and protect against UV-induced damage, making it suitable for treating , burns, and . The global mucin cosmetic market reached $555 million in 2022 and approximately $750 million as of 2025, driven by demand in Asian skincare markets. In nutricosmetic formulations, orally administered snail mucin has shown potential to counteract UVB-induced by preserving integrity and reducing depth in animal models. Its biocompatibility and low allergenicity further support its use in sensitive products, with studies indicating accelerated closure—up to 23% faster in models—due to enhanced and . Beyond topical applications, marine-derived mucins from cnidarians are emerging in for maintaining hydration and barrier protection, leveraging their structure to mimic natural layers. Industrial applications of mucins extend to and , where recombinant mucins engineered via mammalian cell systems enable scalable production with customized glycan profiles for targeted functionalities. These engineered mucins serve as backbones for hydrogels in and systems, providing tunable viscosity, adhesion, and immunomodulatory effects to improve implant integration and resistance. For instance, mucin-stabilized nanoparticles have been developed for controlled release of therapeutics, enhancing —such as 92% release for metformin in patches—while leveraging mucin's bioadhesive properties. In food and packaging industries, snail mucin acts as a natural plasticizer in hydroxypropyl methylcellulose-based films, improving mechanical strength, water vapor permeability, and UV barrier properties for sustainable, edible coatings. Bovine submaxillary mucin, complexed with silver nanoparticles, demonstrates strong antibacterial activity, offering potential in antimicrobial coatings and infection-preventive materials for agricultural and biomedical uses. Purification techniques, such as filtration-based methods, facilitate cost-effective extraction of functional mucins for these applications, yielding high-purity products suitable for large-scale industrial processing. Overall, mucins' versatility positions them as key components in eco-friendly biomaterials, with ongoing research emphasizing sustainable sourcing to support broader adoption.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11906035/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4663118/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC9238349/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8442341/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2847370/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC2951677/
  7. https://pubmed.ncbi.nlm.nih.gov/11578969/
  8. https://www.ncbi.nlm.nih.gov/gene/283463
  9. https://www.genenames.org/data/genegroup/#!/group/648
  10. https://www.imrpress.com/journal/FBL/6/3/10.2741/Fowler/pdf
  11. https://www.jci.org/articles/view/115360
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC4868133/
  13. https://www.nature.com/articles/s41467-022-31062-4
  14. https://doi.org/10.1073/pnas.0705984104
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2835492/
  16. https://doi.org/10.1096/fj.07-9673rev
  17. https://www.pnas.org/doi/10.1073/pnas.0705984104
  18. https://www.sciencedirect.com/science/article/pii/S0378111906000266
  19. https://www.science.org/doi/10.1126/sciadv.abm8757
  20. https://www.science.org/doi/10.1126/science.adl0882
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC5812724/
  22. https://www.nature.com/articles/s41392-024-01886-1
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC9688771/
  24. https://www.cell.com/cell/fulltext/S0092-8674(20)31162-4
  25. https://www.sciencedirect.com/science/article/pii/S0959440X22002032
  26. https://www.nature.com/articles/s41598-018-24223-3
  27. https://journals.physiology.org/doi/full/10.1152/physiolgenomics.00088.2012
  28. https://www.nature.com/articles/s12276-023-00960-y
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9068269/
  30. https://doi.org/10.1073/pnas.0803124105
  31. https://doi.org/10.1038/nature12807
  32. https://doi.org/10.1021/bm0609691
  33. https://doi.org/10.1006/exer.2001.1045
  34. https://doi.org/10.1146/annurev.physiol.70.113006.100702
  35. https://doi.org/10.1146/annurev-biochem-011520-105053
  36. https://doi.org/10.3389/fphys.2023.1284423
  37. https://doi.org/10.1093/femsre/fuy002
  38. https://doi.org/10.1126/science.1109051
  39. https://doi.org/10.1038/nrmicro2776
  40. https://doi.org/10.1016/j.chom.2008.11.002
  41. https://doi.org/10.1073/pnas.0804874105
  42. https://doi.org/10.1126/science.aao5774
  43. https://www.researchgate.net/publication/301241054_Searching_the_Evolutionary_Origin_of_Epithelial_Mucus_Protein_Components-Mucins_and_FCGBP
  44. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.734023/full
  45. https://academicworks.cuny.edu/cgi/viewcontent.cgi?article=1849&context=hc_sas_etds
  46. https://www.mdpi.com/2077-1312/13/3/566
  47. https://www.pnas.org/doi/10.1073/pnas.94.13.6977
  48. https://www.sciencedirect.com/science/article/pii/S0021925818701506
  49. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.00551/full
  50. https://royalsocietypublishing.org/doi/10.1098/rstb.2023.0078
  51. https://www.pagepressjournals.org/aiol/article/view/11054/10762
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC7500085/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC6853602/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC10344637/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC8570975/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC10046558/
  57. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70510-2/abstract
  58. https://aacrjournals.org/clincancerres/article/17/12/4091/11912/Treatment-of-Advanced-Pancreatic-Carcinoma-with
  59. https://www.nature.com/articles/s41698-025-01016-2
  60. https://jitc.bmj.com/content/13/11/e013120
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC4469994/
  62. https://doi.org/10.1016/j.actbio.2025.05.006
  63. https://doi.org/10.1016/j.jddst.2020.101845
  64. https://doi.org/10.1111/j.1468-2494.2011.00654.x
  65. https://www.coherentmarketinsights.com/market-insight/snail-beauty-products-market-1393
  66. https://doi.org/10.1016/j.jddst.2021.102678
  67. https://doi.org/10.1038/s41467-023-35907-4
  68. https://doi.org/10.1016/j.addr.2022.114618
  69. https://doi.org/10.1016/j.foodchem.2022.133456
  70. https://pubmed.ncbi.nlm.nih.gov/29180363/
  71. https://doi.org/10.3389/fbioe.2021.734023
Add your contribution
Related Hubs
User Avatar
No comments yet.